In early lung cancer patients surgery is your first therapy option. If surgery is not an option then stereotactic body radiotherapy (SBRT) is the next best therapy. Like all toxic therapies for any cancer at any stage, there are side effects to consider. Each patient is different, of course.
As the meta description above quotes, lung cancer patients must be wary of toxicity of SBRT. As the study linked below explains there are evidence-based, non-toxic therapies that can both enhance therapy as well as reduce toxic side-effects.
I am a cancer survivor and cancer coach. I have lived in complete remission from my “incurable” cancer since ’99 by living an evidence-based, non-toxic lifestyle through nutrition, supplementation and more.
To learn more about evidence-based therapies for lung cancer, please watch the short video below:
Have you been diagnosed with lung cancer? What stage? For more information about both conventional and non-conventional lung cancer therapies scroll down the page, post a question or comment and I will reply to you ASAP.
“Here, we show that RV treatment enhances IR-induced cell killing in non-small cell lung cancer (NSCLC) cells through an apoptosis-independent mechanism…”
“For early-stage lung cancer, the treatment of choice is surgery. In patients who are not surgical candidates or are unwilling to undergo surgery, radiotherapy is the principal treatment option…
Patients who are diagnosed at early stages can undergo surgical resection and account for 20-25% of cases. However, 20-30% of such patients are not surgical candidates or are unwilling to undergo surgery.2 Median survival is 13 months for patients with untreated T1 tumors and 8 months for those with untreated T2 tumors, the 5-year cancer-specific survival rate being 16%.3
Therefore, a therapeutic intervention is warranted in this group of inoperable patients, radiation therapy being the traditional alternative…
Various techniques can be used, ranging from-
However, in patients with stage I lung cancer, the results of conventional radiation therapy are markedly inferior to those of surgery, with local recurrence rates of up to 70%.(4-6)
Stage I or II NSCLC patients, who have no lymph node involvement and who are medically inoperable, constitute the target population for SBRT. Although there have been reports of SBRT in patients with tumors of up to 10 cm in diameter, mean tumor diameter is 3 cm, and consensus dictates that patients with lesions ≤ 5 cm in diameter can be treated with SBRT. Cases of tumor recurrence and metastatic lesions can also be treated with SBRT.13…”